Trust Co. of Oklahoma Makes New Investment in Edwards Lifesciences Co. (NYSE:EW)

Trust Co. of Oklahoma purchased a new position in shares of Edwards Lifesciences Co. (NYSE:EW) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 3,121 shares of the medical research company’s stock, valued at approximately $298,000.

Other large investors have also made changes to their positions in the company. DSM Capital Partners LLC bought a new position in shares of Edwards Lifesciences during the fourth quarter valued at $28,000. Turtle Creek Wealth Advisors LLC bought a new position in shares of Edwards Lifesciences during the fourth quarter valued at $34,000. Riverview Trust Co bought a new position in shares of Edwards Lifesciences during the first quarter valued at $34,000. Pingora Partners LLC bought a new position in shares of Edwards Lifesciences during the fourth quarter valued at $38,000. Finally, SRS Capital Advisors Inc. raised its stake in shares of Edwards Lifesciences by 292.6% during the third quarter. SRS Capital Advisors Inc. now owns 636 shares of the medical research company’s stock valued at $44,000 after acquiring an additional 474 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insiders Place Their Bets

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,250 shares of the business’s stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $85.80, for a total value of $622,050.00. Following the completion of the sale, the chief financial officer now directly owns 19,074 shares of the company’s stock, valued at $1,636,549.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CFO Scott B. Ullem sold 7,250 shares of the company’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $85.80, for a total transaction of $622,050.00. Following the completion of the transaction, the chief financial officer now directly owns 19,074 shares of the company’s stock, valued at $1,636,549.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Bernard J. Zovighian acquired 580 shares of the stock in a transaction dated Monday, May 6th. The shares were purchased at an average cost of $85.74 per share, with a total value of $49,729.20. Following the completion of the purchase, the chief executive officer now owns 3,268 shares of the company’s stock, valued at approximately $280,198.32. The disclosure for this purchase can be found here. Insiders sold 119,849 shares of company stock valued at $10,579,038 over the last three months. Insiders own 1.27% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of EW traded down $0.14 during mid-day trading on Wednesday, reaching $91.09. 1,497,118 shares of the stock traded hands, compared to its average volume of 3,443,672. The firm has a fifty day moving average price of $87.99 and a 200 day moving average price of $85.56. The company has a market cap of $54.89 billion, a price-to-earnings ratio of 39.26, a price-to-earnings-growth ratio of 3.38 and a beta of 1.11. The company has a current ratio of 3.75, a quick ratio of 2.67 and a debt-to-equity ratio of 0.08. Edwards Lifesciences Co. has a 1 year low of $60.57 and a 1 year high of $96.12.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. The firm had revenue of $1.60 billion during the quarter, compared to analyst estimates of $1.58 billion. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. As a group, equities research analysts predict that Edwards Lifesciences Co. will post 2.77 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Citigroup upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $98.00 to $105.00 in a research report on Wednesday, May 22nd. Deutsche Bank Aktiengesellschaft upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and raised their price target for the stock from $86.00 to $103.00 in a report on Tuesday, May 14th. Morgan Stanley raised their price target on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the stock an “overweight” rating in a report on Thursday, March 21st. StockNews.com upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Thursday, June 27th. Finally, Wells Fargo & Company lifted their price objective on shares of Edwards Lifesciences from $94.00 to $99.00 and gave the company an “overweight” rating in a report on Friday, April 26th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and an average target price of $95.18.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.